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ABSTRACT 
Immunotherapy is one of the most promising strategies for the treatment of cancer. Human 
papillomavirus (HPV) is responsible for virtually all cases of cervical cancer. The main purpose 
of a therapeutic HPV vaccine is to stimulate CD8
+
 cytotoxic T lymphocytes (CTLs) that can 
eradicate HPV infected cells. HPV oncoproteins E6 and E7 are continuously expressed and are 
essential for maintaining the growth of HPV-associated tumor cells. We designed polymer-based 
multi-antigenic formulations/constructs that were comprised of the E6 and E7 peptide epitopes. 
We developed an N-terminus-based epitope conjugation to conjugate two unprotected peptides to 
poly tert-butyl acrylate. This method allowed for the incorporation of the two antigens into a 
polymeric dendrimer in a strictly equimolar ratio. The most effective formulations eliminated 
tumors in up to 50% of treated mice. Tumor recurrence was not observed up to 3 months post 
initial challenge. 
 
1. Introduction 
Human papilloma viruses (HPVs) are the main cause of cervical cancer.
1
 There are currently 
two prophylactic HPV vaccines, Gardasil and Cervarix, that have been developed and 
commercialized to the global market.
2
 However, they are only recommended for naïve females 
aged from 9 to 26, and not for women already infected with HPVs.
3
 For this reason, a new 
therapeutic vaccine is required for the treatment of the HPV-infected population. 
In the last few decades, peptide-based subunit vaccines emerged as promising prophylactic 
and/or therapeutic medicines against several infectious diseases.
4
 The main components of 
peptide-based subunit vaccines are the small peptides derived from the protein of a targeted 
pathogen.
5
 In contrast to whole-cell or protein vaccines, vaccine non-redundant peptide 
components are non-toxic and non-infectious, and significantly lower the risks of allergic and/or 
autoimmune responses in patients.
6
 They have high specificity as their peptide epitopes are 
purposely designed to recognize certain pathogenic targets. The pure peptides are easily 
produced under simple and economical methods, and microbe culturing is not required. They are 
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usually water-soluble and stable at room temperature, and do not require special storage 
conditions. The use of a peptide-based approach in the development of therapeutic anticancer 
vaccines in contrast to whole oncogenic proteins reduces the risk of vaccine-induced side-effects. 
However, one of the drawbacks of using peptides is that they require adjuvants as 
immunostimulant agents to trigger the desired immune responses. Commercially available 
adjuvants are often weak inducers of anticancer immune responses and/or toxic, and, therefore, 
new delivery platforms/adjuvants are needed.
6, 7
  
To be effective, a therapeutic vaccine must be able to induce antitumor T-lymphocyte 
responses to directly kill cancer cells and, subsequently, to regress tumor growth.
8
 The 
identification of appropriate peptide epitopes capable of initiating effective antitumor T-
lymphocyte responses is critical for the design of a therapeutic vaccine.
9
 HPV oncoproteins E6 
and E7 are continuously expressed and are essential for maintaining the growth of HPV-
associated tumor cells. Therefore, E643-57 (QLLRREVYDFAFRDL)
10
 and E744-57 
(QAEPDRAHYNIVTF) epitopes were chosen for this study. E744-57 contains a CD4
+
 T helper 
cell epitope (E748-54, DRAHYNI) and a CD8
+
 T cell epitope (E749-57, RAHYNIVTF),
11, 12
 
similarly E643-57 also includes both CD4
+
 and CD8
+
 epitopes.
13
 Recently, we showed that E744-57 
conjugated to a polymeric delivery system was able to eradicate E7-expressing tumor cells in 
immunized mice.
11, 12, 14
 tert-Butyl acrylate polymer was chosen as a delivery platform for the 
vaccine because of its safety profile
15
 and ability to serve as a self-adjuvanting moiety to induce 
both strong humoral and cellular immune responses.
16-18
  
In all of the previous challenge experiments, vaccine candidates were used to treat small 
tumors, as the vaccines were administered 3 days post tumor implantation. However, ideal 
therapeutic vaccines should also be able to eradicate large, well-established tumors. 
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Unfortunately, the trialed therapeutic vaccine candidates often failed to demonstrate this desired 
efficacy when used for the treatment of advanced cancer, in both mice models and human 
clinical trials.
19
 
Here, we describe the synthesis of vaccine candidates 1-7 (Figure 1) and the biological 
evaluation of their ability to eradicate TC-1 tumors from female C57Bl/6 mice. In contrast to 
previous studies, one of the main purposes of this work is to synthesize and test multiantigenic 
polymer-based vaccine delivery system, carrying both E6 and E7 protein-based epitopes, against 
7 day well-established tumors in challenge experiments. 
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Figure 1. Vaccine candidates 1-7. 
 
2. Results and Discussion 
Synthesis and characterization of polymer-peptide conjugates 
Vaccine candidates 1-4 (Figure 1) were synthesized as described previously.
14
 Vaccine 
candidate 5 was synthesized through CuAAC between the alkyne-functionalized poly(t-butyl 
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acrylate) (8)
11
 and the azido acetic acid derivative of E6
43-57
 epitope (9, N
3
CH
2
CO- 
QLLRREVYDFAFRDL-NH
2
)
20
 (Scheme 1).  
 
Scheme 1. Synthesis of conjugate 5. 
As the synthesis and evaluation of multiantigenic peptide-polymer carrying both E6 and E7 
derived epitopes is one of our main purposes in this work, and the N-terminus conjugation of 
them is required for their activity,
11
 the application of appropriate conjugation strategy is crucial 
for production of desired multicomponent vaccine candidates. Conjugation of peptides, became a 
popular approach for the synthesis of chemically engineered biomolecules for various biological 
applications.
21
 Peptides ligation is a smart solution to overcome the obstacles in obtaining large 
homogeneous peptides with more than 50 amino acids by using solid phase peptide synthesis 
(SPPS).
22
 Many peptide ligation techniques were revealed for the conjugation of two peptides via 
the binding of amino (N) terminal of one of the peptides to the carboxy (C) terminal of the other 
one.
23
 However, a very few number of research focused on peptide conjugation through their N-
terminals. Johnson et al. coupled two copies of an unprotected erythropoietin receptor agonist 
peptide from their N-terminals by employing an amine-reactive difunctional polyethylene glycol 
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(PEG) molecule, succinimidyl propionate, to form a linear polymer molecule.
24
 The presence of 
an amine group in the side chain of a single lysine within the peptide sequence led to formation 
of undesired bindings and difficulties in purifications. Szewczuk and co-workers carried out 
successfully an N-terminal N-terminal dimerization of a peptide fragment on SPPS by using 
polyethylene glycols spacer; however, the use of fully protected peptides was required.
25,26
  
Liskamp and his team were able to conjugate 3 different unprotected cyclic peptides to trialkynes 
scaffold through copper-catalyzed alkyne-azide cycloaddition (CuAAC) reaction; however, the 
control of substitution ratio was difficult.
27
   
Conjugation of dendrimer 8 with a mixture of azides 9 and 10 (N
3
CH
2
CO-
QAEPDRAHYNIVTF-NH
2
)
11, 28
 via CuAAC was expected to produce a mixture of constructs 
with different contents of E6
43-57
 and E7
44-57
 epitopes conjugated to dendrimer, and a model 
experiment was designed to optimize the conjugation conditions. A mixture of azides 9 and 10 
was added in different ratios to a model tetra-alkynes peptide (11) in the presence of copper wire 
(Figure 2a). Treatment of tetra-alkynes (11) with 6 equivalents of 9 and 2 equivalents of 10 (ratio 
6:2) was found to be optimal to obtain compound 6 possessing the most equal contents of both 
epitopes (Figure 2b and Table 1). Thus, epitopes 9 and 10 (in molar ratio 6:2) were conjugated to 
dendrimer 8 to produce multiepitope construct 6 (Scheme 2).  
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Figure 2. (a) Synthesis of model compound 12. (b) Results of monitoring the CuAAC reaction between the model 
tetra-alkynes 11 and azides 9 and 10.  (8 equivalents in total of azides were used for conjugation in different ratio 
aspects). (i) The reaction at 0 time. The ratio of 9:10 was: (ii) 6.5:1.5; (iii) 6:2; (iv) 5:3; (v) 4:4.  
Table 1. The yield of the conjugation between azides 9 and 10 and alkyne 11 based on the HPLC traces 
integration. 
Equivalents ratio of 
9 : 10 
Products 
0/4 
12a 
1/3 
12b 
2/2 
12c 
3/1 
12d 
4/0 
12e 
4:4 39% 34% 14% 5% 2% 
5:3 33% 39% 16% 5% 1% 
6:2 8% 28% 24% 17% 21% 
6.5:1.5 3% 21% 23% 18% 33% 
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Scheme 2. Synthesis of conjugate 6.  
Despite the optimization of the production of compound 6, this vaccine candidate produced 
a rather poorly controlled mixture of several conjugates. Thus, to achieve a well-defined vaccine 
candidate in a reproducible manner, a recently developed double conjugation strategy was 
proposed.
20
 First, an acryloyl derivative of E6
43-57 
(13) was conjugated to the mercapto-azide 
derivative of E7
44-57
 (14) at pH ~7.3 to produce compound 15 in 90% yield (Scheme 3).
20
 The 
azide 15 was then conjugated to the dendrimer 8 in the presence of Cu wire to give 7 (Scheme 3). 
  
 11 
 
Scheme 3. Synthesis of conjugate 7. 
Vaccine candidates 1-7 were all self-assembled into particles via the solvent replacement 
method (DMF/water).
11
 Excess unreacted peptides, copper, and organic solvents were removed 
by extensive dialysis against water.  
Conjugation efficiency was proven by elemental analysis, as previously reported.
11, 16
 A 
significant increase in the nitrogen/carbon ratio (N/C) (Table 2), compared to that of polymer 
(N/C = 0.004 for L1 (one arm polymer) and S4 (4 arms polymer); N/C = 0.02 for L2 (one arm 
polymer with two alkyne groups) and D8 (4 arms polymer with 8 alkyne groups)), was apparent, 
due to the presence of nitrogen-rich peptide in the conjugates. The calculation of the substitution 
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ratio of either E6
43-57
 and/or E7
44-57
 conjugated to each polymer was based on the comparison of 
the observed and theoretical N/C ratio for the conjugates, as reported previously.
11, 14
 The obtained 
substitution ratio was high to excellent (Table 2).  
Table 2. Substitution ratio for conjugates 1-7 calculated based on nitrogen/carbon ratio (N/C, 
found by elemental analysis). 
Compound N/C Substitution Ratio 
1 0.082 96% 
2 0.143 98% 
3 0.078 88% 
4 0.124 76% 
5 0.136 79% 
6 0.141 87% 
7 0.196 90% 
 
To prepare samples for in vivo experiments, all polymer-peptide conjugates
 
were 
formulated in phosphate buffered saline (PBS). At pH 7.4, conjugates 1-7 formed a milky 
suspension in PBS. The particle size of each polymer-peptide conjugate was analyzed by laser 
particle size analysis (Table 3).  
Table 3. Average particle size of the final constructs 1-7. 
Compound Diameter  
 (µm) 
Span 
1 17 2 
2 13 1.7 
3 13 1.1 
4 14 1.7 
5 -
1 
-
1 
6 143 1.5 
7 106 1.7 
1
 Highly polydisperse precipitating aggregates (laser diffraction could not determine their sizes). 
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Figure 3. In vivo E6/E7-expressing TC-1 tumor treatment experiments. C57Bl/6 mice (10 per group) were 
inoculated subcutaneously in the flank with 2  10
5 
TC-1 cells/mouse (day 0), and injected with (a) compound 1-4 
and controls on day 7. Survival rate was monitored and time to death plotted on a Kaplan-Meier survival curve. Mice 
were sacrificed when the tumor volume became greater than 1 cm
3
 or started bleeding. The survival rate of each 
group was compared to the positive control (E7
44-57 
+ ISA51), and was analyzed by the long-rank test (ns = p > 0.05; 
* = p  0.05; ** = p  0.01; *** = p  0.001; **** = p  0.0001). (b) Mean tumor volume (cm
3
) of mice vaccinated 
with compounds 1-4 and controls was monitored and plotted until the first mouse from any group reached the 
endpoint (day 27). (c) Kaplan-Meier survival curve for mice vaccinated with compounds 4-7 and controls. The 
survival rate of each group was compared to the negative control (PBS). (d) Mean tumor volume (cm
3
) of mice 
vaccinated with compound 4-7 and controls was monitored and plotted until the first mouse from any group reached 
the endpoint (day 24). 
  
In vivo tumor treatments 
Previous studies have shown that the peptide epitope E7
44-57
 conjugated with four different 
polyacrylate polymer analogs (1-4) was able to generate a robust therapeutic immunity against 
HPV-16 E6/E7-expressing TC-1 tumors after a single-dose immunization on day 3 post tumor 
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challenge.
12, 14
 To further test the antitumor efficacy of polymer-peptide conjugates 1-4 to control 
well-established, solid tumors, mice (10 per group) were vaccinated on day 7 (instead of day 3) 
after tumor cell implantation. All mice received a single-dose treatment without additional 
boosts. The positive control group received E7
44-57
 emulsified in 1:1 Montanide ISA51/PBS (IFA-
like adjuvant) (E7
44-57 
+ ISA51).
29
 The untreated group was administered PBS. Tumor-bearing 
mice immunized with compounds 1-4 and the positive control showed significantly prolonged 
survival and slower tumor growth when compared with the untreated PBS group (Figure 3a; b; 
S1). The antitumor activity elicited by compound 3 was similar to that of positive controls (as 
observed in previous studies).
11, 14
 In contrast, mice treated with compounds 1, 2 and 4 
demonstrated a significantly enhanced therapeutic effect compared to positive controls (p  0.05 
for compounds 2 and 4; p  0.01 for compound 1). Furthermore, at day 27 post tumor challenge, 
the average tumor size in mice immunized with vaccine candidates 1, 2 and 4 were smaller than 
those in mice immunized with either vaccine candidate 3 or the positive control (Figure 3b). 
Interestingly, in all groups treated with compounds 1-4, at least one mouse survived 80 days post 
tumor implantation, while all mice were moribund in the group treated with commercial adjuvant 
(positive control) by day 50. Unfortunately, the efficacy of vaccine candidates 1-4 was 
significantly reduced in established tumors compared to the results from small, “young” tumor 
challenges, as reported previously.
14
  
In order to enhance the therapeutic efficacy of these polyacrylate-peptide conjugates, 
additional epitope E6
43-57
 derived from HPV-16 E6 oncoprotein was conjugated to 8-arm dendritic 
polymer to produce compounds 5-7 and administered into mice alone (6, 7) or as a physical 
mixture (i.e. 4 + 5). Compound 4 was administered using both single-dose and boost regimes. 
Peptides E6
43-57
 and E7
44-57
 emulsified in 1:1 Montanide ISA51/PBS (E6
43-57 
+ E7
44-57 
+ ISA51) were 
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used as positive controls. Mice were immunized with a single injection on day 7 post tumor 
challenge, except for compound 4, where mice received additional boosts on day 14 and 21.  
The Kaplan-Meier survival curve (Figure 3c) indicates that tumor-bearing mice vaccinated 
with compounds 6 and 7 had an improved survival rate (p  0.05) compared to the untreated PBS 
group, while compounds 4, 4-boost, 4 + 5 and Montanide-adjuvanted epitopes exhibited an 
enhanced therapeutic efficacy (p  0.001). Particularly, 4-boost and the physical mixture 4 + 5 
induced the most significant antitumor activity (p  0.0001) of the above vaccine formulations, 
leading to five and four tumor-free mice, respectively, at the end of the challenge in each group 
(Figure S2), and ongoing as at 3 months after the initial challenge. Interestingly, the physical 
mixture of compounds 4 + 5, which contained E6
43-57
 and E7
44-57
 epitopes, was more efficient than 
the same epitopes presented in conjugated form in compound 7.  
As shown in the tumor growth curve (Figure 3d), the mice that received a single-dose or 
boost regiment of compound 4 showed similar efficacy in tumor suppression on day 24. 
Furthermore, no significant difference was found in survival rate comparisons of single-dose 
versus boost regimes. Interestingly, although these polymer-based delivery systems were highly 
efficient in inducing humoral and cellular immunity after single dose administration,
11, 14, 16, 18
 
multiple administration of vaccine candidate 4-boost did not significantly improve the efficacy of 
cellular immune responses.  
Compound 5 alone did not induce a significant improvement in the survival rate (Figure 
3c) or slow tumor growth in mice (Figure S2c), suggesting that the formation of large aggregates 
of compound 5 in solution may have diminished its potency to induce an immune response. 
Compounds 6 and 7, which were the constructs possessing both E6/E7 epitopes conjugated to the 
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same polyacrylate dendrimer, produced much weaker anti-tumor activity compared to the 
physical mixture of two dendritic constructs containing E7 and E6 epitopes (4 + 5 physical 
mixture). It has been considered that the uptake of particles by antigen presenting cells (APCs) 
plays a crucial role in the induction of immune responses for particle-based vaccines.
30, 31,32
 Large 
particles usually have an efficient depot effect for continuous antigen release.
31, 33
 We have proven 
that polyacrylate polymers conjugated to the E7 epitope formed microparticles (12-17 m), 
which were able to be efficiently taken up by APCs (including macrophages and dendritic cells), 
as well as to activate CD8
+
 and CD4
+
 cells to elicit adequate cellular immune responses against 
E7-expressing tumors.
14
 However, it has been reported that very large-sized particles ranging 
from 50-100 m (which is larger than a typical APC) were least likely to be taken up by APCs, 
resulting in the generation of a low immune response.
31
 Conjugates 6 and 7 formed large 
microparticles (143 µm and 106 µm, respectively), while construct 5 formed large, highly 
polydisperse aggregates (laser diffraction could not determine their sizes). Therefore, limited 
improvement in the efficacy upon incorporation of the E6 epitope into polymer-based vaccine 
might be related to the hydrophobic properties of the epitope, which cause extensive aggregation 
of the conjugates bearing it. Thus, the presence of E7
44-57 
epitope was essential to produce a robust 
CTL response and these cellular immune responses were dependent on the size of particles; 
smaller particles induced stronger CTL responses than larger. 
 
3. CONCLUSION         
Considering the heterogeneity of the human immune response against any one given 
antigenic epitope, the incorporation of more than one epitope in a proposed vaccine delivery 
system is more likely to achieve consistent clinical success. A polymer-peptide conjugate 
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delivery system can bear multiple copies of the same peptide epitope in one construct and is able 
to generate potent therapeutic immunity when formulating conjugates in a simple physical 
mixture, without adding external adjuvant after a single-dose vaccination. Importantly, this 
delivery system resulted in the elimination of tumors in mice and tumor recurrence was not 
observed for 3 months after the initial challenge. Our finding suggests that this novel self-
adjuvanting delivery system would provide a safe, efficient therapeutic vaccine that is effective 
for the broader population. However, it is important to note that polar properties of the epitopes 
may significantly influence the efficacy of such polymer-based vaccines, as hydrophobic 
epitopes may trigger the formation of large aggregates with a limited potency to deliver desired 
immune responses. To overcome formation of such aggregates, hydrophilic moieties, for instance 
polyethylene glycol or polyglutamic acid, could be incorporated to increase the hydrophilic 
character of the epitopes and consequently reduce the particle size of the final constructs. 
 
4. Experimentals 
Protected L-amino acids were purchased from Novabiochem (Läufelfingen, Switzerland) and 
Mimotopes (Melbourne, Australia). pMBHA resin was purchased from Peptides International 
(Kentucky, USA). Rink amide MBHA resin, N,N’-dimethylformamide (DMF), dichloromethane 
(DCM), methanol, N,N’-diisopropylethylamine (DIPEA), piperidine and trifluoroacetic acid 
(TFA) were obtained from Merck (Hohenbrunn, Germany). (Dimethylamino)-N,N-dimethyl(3H-
[1,2,3]triazolo[4,5-b]pyridin-3-yloxy)-methanim-inium hexafluorophosphate (HATU) was 
purchased from Mimotopes (Melbourne, Australia). HPLC grade acetonitrile was obtained from 
Labscan (Bangkok, Thailand). Cu wires were purchased from Aldrich (Steinheim, Germany). t-
Butyl acrylate (
t
BA, Aldrich, >99 %) was deinhibited before use by passing through a basic 
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alumina column, Ethyl 2-bromoisobutyrate (EBiB, Aldrich, 98 %), tripropargylamine (TPA, 
Aldrich, 98 %), sodium azide (NaN3, Aldrich, ≥ 99.5 %), dimethyl sulfoxide (DMSO, Labscan, 
AR grade), N,N,N’,N’,N’’-pentamethyldiethylenetri-amine (PMDETA, Aldrich, 99 %), 
copper(I) bromide (Cu(I)Br, MV Laboratories, INC., 99.999 %), copper(II) bromide (CuBr2, 
Aldrich, 99 %) were used as received. Propargyl nitroxde was synthesized according the 
previously reported procedure.
34
 All other reagents were obtained at the highest available purity 
from Sigma-Aldrich (Castle Hill, NSW, Australia). Anhydrous hydrofluoric acid (HF) was 
supplied by BOC gases (Sydney, NSW, Australia). A Kel-F HF apparatus (Peptide Institute, 
Osaka, Japan) was used for HF cleavage. ESI-MS was performed using a Perkin-Elmer-Sciex 
API3000 instrument with Analyst 1.4 software (Applied Biosystems/MDS Sciex, Toronto, 
Canada). Analytical RP-HPLC was performed using Shimadzu (Kyoto, Japan) instrumentation 
(DGU-20A5, LC-20AB, SIL-20ACHT, SPD-M10AVP) with a 1 mL min
−1
 flow rate and 
detection at 214 nm and/or evaporative light scattering detector (ELSD). Separation was 
achieved using a 0-100% linear gradient of solvent B over 40 min with 0.1% TFA/H2O as solvent 
A and 90% MeCN/0.1% TFA/H2O as solvent B on either a Vydac analytical C4 column 
(214TP54; 5 m, 4.6 mm x 250 mm) or a Vydac analytical C18 column (218TP54; 5 m, 4.6 
mm x 250 mm). Preparative RP-HPLC was performed on Shimadzu (Kyoto, Japan) 
instrumentation (either LC-20AT, SIL-10A, CBM-20A, SPD-20AV, FRC-10A or LC-20AP x 2, 
CBM-20A, SPD-20A, FRC-10A) in linear gradient mode using a 5-20 mL/min flow rate, with 
detection at 230 nm. Separations were performed with solvent A and solvent B on a Vydac 
preparative C18 column (218TP1022; 10 m, 22 mm x 250 mm), Vydac semi-preparative C18 
column (218TP510; 5 m, 10 mm x 250 mm) or Vydac semi-preparative C4 column (214TP510; 
5 m, 10 mm x 250 mm). The particle size distribution and measurement of the average particle 
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size were analyzed using a laser particle size analyzer Mastersizer 2000 (Malvern Instruments, 
England, UK). Multiplicate measurements were performed, and the average particle size was 
represented. The level of copper traces presented in the polymer-peptide conjugates was 
precisely determined by inductively-coupled plasma optical emission spectrometer (Perkin-
Elmer Optima 8300DV (Dual View), USA). The copper content of conjugates 1-7 was below 
100 ppb (the recommended health standard level of copper is ≤ 15 ppm).35 
Synthesis of E744-57 Peptide
11
  
E744-57 epitope (QAEPDRAHYNIVTF) was synthesized by manual stepwise SPPS on pMBHA 
resin (substitution ratio: 0.45 mmol/g, 0.2 mmol scale, 0.44g) using HATU/DIPEA Boc-
chemistry. Boc-amino acids were preactivated for 1 min prior to their addition to the resin. The 
activation of amino acids was achieved by dissolving Boc-amino acid (0.84 mmol, 4.2 equiv.), in 
0.5 M HATU/DMF solution (1.6 mL, 0.8 mmol, 4.0 equiv.) followed by the addition of DIPEA 
(0.22 mL, 1.24 mmol, 6.2 equiv.). Coupling cycle consisted of Boc deprotection with neat TFA 
(2 × 1 min, at rt), a 1 min DMF flow-wash, followed by coupling with 4.2 equiv. of preactivated 
Boc-amino acids (2 × 1 h). For peptides containing His(DNP) residues, the DNP (2,4-
dinitrophenyl) group was cleaved by treating the resin with 20% (v/v) -mercaptoethanol and 
10% (v/v) DIPEA in DMF for 2 × 1 h treatments prior to peptide cleavage. Upon completion of 
synthesis and removal of the dinitrophenyl (DNP) protecting group, the resin was washed with 
DMF, DCM, and MeOH, then dried (vacuum desiccator). The peptide was cleaved from the resin 
using HF, with p-cresol as a scavenger. The cleaved peptide was precipitated, filtered, and 
washed thoroughly with ice-cold Et2O and dissolved in 50% MeCN/0.1% TFA/H2O. After 
lyophilization the crude peptide was obtained as an amorphous powder. The product was purified 
by preparative RP-HPLC on C18 column with a solvent gradient of 15-35% solvent B over 20 
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min. HPLC analysis (C18 column): tR = 16.7 min, purity > 95%. Yield: 27%. ESI-MS: m/z 
1661.1 (calc 1660.8) [M+H]
+
; 830.8 (calc 830.9) [M+2H]
2+
; MW 1659.8. 
General procedure of manual stepwise SPPS on rink amide MBHA resin - Fmoc-chemistry  
Peptides were synthesized by manual stepwise SPPS on rink amide MBHA resin (substitution 
ratio: 0.60 mmol/g, 0.2 mmol scale, 0.33 g) using HATU/DIPEA Fmoc-chemistry. Amino acid 
activation was achieved by dissolving Fmoc-amino acid (0.84 mmol, 4.2 equiv.), in 0.5 M 
HATU/DMF solution (1.6 mL, 0.8 mmol, 4.0 equiv.) followed by the addition of DIPEA (146 
L, 0.84 mmol, 4.2 equiv.). Coupling cycle consisted of Fmoc deprotection with 20% of 
piperidine in DMF (twice, 10 and 20 min), a 1 min DMF flow-wash, followed by coupling with 
4.2 equiv. of preactivated Fmoc-amino acids (2 × 1 h). Upon completion of synthesis, the resin 
was washed with DMF, DCM, and MeOH, then dried (vacuum desiccator). The cleavage of 
peptide was carried out by stirring the resin in the solution of TFA (99%)/triisopropylsilane/water 
(95:2.5:2.5) for 4 h. The cleaved peptide was precipitated, filtered, and washed with ice-cold 
Et2O. After lyophilization the crude peptide was obtained as an amorphous powder. After 
purification of peptides, the yields of purification were calculated based on the mass of peptide as 
a TFA salt.  
Synthesis of E6
43-57
 peptide
20
  
E6
43-57
 epitope (QLLRREVYDFAFRDL; E6
43-57
) was synthesized following the general procedure 
Fmoc-SPPS described above. The crude product was purified by preparative RP-HPLC on C-18 
column with solvent gradient 25-45% solvent B over 20 min. HPLC analysis (C-18 column): t
R
 = 
19.8 min, purity > 95%. Yield: 84%. ESI-MS: m/z 970.9 (calc 971.1) [M+2H]
2+
; 647.8 (calc 
647.7)  [M+3H]
3+
; MW 1940.2. 
Synthesis of N-terminus E6
43-57
-azide (9)
20
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N-terminus E6
43-57
-azide peptide epitope (9, N
3
CH
2
CO-QLLRREVYDFAFRDL) was synthesized 
following the Fmoc-SPPS procedure. The attachment of azidoacetic acid (4.2 equiv.) was 
achieved using HATU (3 equiv.)/DIPEA (4.2 equiv.) at room temperature (2 × 1 h) and the 
reaction mixture was covered and protected from light with aluminum foil. The crude product 
was purified by preparative RP-HPLC on C-18 column with solvent gradient 35-55% solvent B 
over 20 min. HPLC analysis (C-18 column): t
R
 = 23.3 min, purity > 95%. Yield: 50%. ESI-MS: 
m/z 1012.8 (calc 1012.6) [M+2H]
2+
; 675.7 (calc 675.4) [M+3H]
3+
; MW 2023. 
Synthesis of N-terminus E7
44-57
-azide (10)
11
  
 N-terminus E7
44-57
-azide peptide epitope (10, N
3
CH
2
CO-QAEPDRAHYNIVTF) was synthesized 
following the general procedure by Fmoc-SPPS. Fmoc deprotection of Thr, Val, and Ile were 
performed with 2% of 1,8-diazabicycloundec-7-ene (DBU) in DMF (twice, 5 and 10 min) instead 
of 20% piperidine in DMF. The attachment of azidoacetic acid (4.2 equiv.) was achieved using 
HATU (3 equiv.)/DIPEA (4.2 equiv.) at room temperature (2 × 1 h) and the reaction mixture was 
covered and protected from light with aluminum foil. The crude product was purified by 
preparative RP-HPLC on C-18 column with solvent gradient 15-35% solvent B over 20 min. 
HPLC analysis (C-18 column): t
R
 = 17.9 min, purity > 95%. Yield: 80%. ESI-MS: m/z 1744.4 
(calc 1743.9) [M+H]
+
; 872.2 (calc 872.9) [M+2H]
2+
; MW 1742.85. 
Synthesis of Dendrimer- E6
43-57 
(5) 
 A mixture of 9 (11.4 mg, 4.8 µmol, 16 equiv.) and 8
16
 (5.8 mg, 0.3 µmol, 1 equiv.) was dissolved 
in DMF (1 mL), and a copper wire (60 mg) was added. The air in the reaction mixture was 
removed by nitrogen bubbling. The reaction mixture was covered and protected from light with 
aluminum foil and stirred at 50 °C under nitrogen for 11 h. The wires were filtered off from the 
warm solution and washed with 1 mL of DMF. Millipore endotoxin-free water (7 mL) was 
slowly added to the solution (0.005 mL/min). Particles formed through the self-assembly process 
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were exhaustively dialyzed against endotoxin-free water using presoaked and rinsed dialysis 
bags. The final formulation was self-assembled into big particles. The laser diffraction method 
was not able to determine their size after formulating the conjugate in PBS. 
Synthesis of model tetra-alkynes (11) 
The Model tetra-alkynes (11) was synthesized following the general Fmoc-SPPS procedure. The 
attachment of propiolic acid (8 equiv.) was achieved using EEDQ (8 equiv.) at room temperature 
(2 × 2 h). The crude product was purified by preparative RP-HPLC on C-18 column with solvent 
gradient 15-35% solvent B over 20 min. HPLC analysis (C-18 column): t
R
 = 17.4 min, purity > 
95%. Yield: 35%. ESI-MS: m/z 757.6 (calc 757.9) [M+H]
+
; MW 756.8.  
 
Synthesis of random multiantigenic-model tetra-alkynes (12a-e) 
 
 A mixture of 9 (2.1 mg, 0.9 µmol, 6 equiv.), 10 (0.6 mg, 0.3 µmol, 2 equiv.) and the model tetra-
alkynes (11, 0.1 mg, 0.15 µmol, 1 equiv.) was dissolved in DMF (0.5 mL), and a copper wire (40 
mg) was added. The air in the reaction mixture was removed by nitrogen bubbling. The reaction 
mixture was covered and protected from light with aluminum foil and stirred at 50 °C under 
nitrogen. The progress of reaction was monitored by analytical HPLC (C-18 column) and ESI-
MS until the tetra-alkynes 11 was completely consumed after 1 h. Compounds 12a-e were 
analyzed by ESI-MS.  
12a: m/z 1547.2 (calc 1546.7) [M+5H]
5+
; 1289.4 (calc 1289.1) [M+6H]
6+
; 1105.4 (calc 1105.0) 
[M+7H]
7+
; MW 7728.3. 
12b: m/z 2003.7 (calc 2003.2) [M+4H]
4+
; 1603.1 (calc 1602.7) [M+5H]
5+
; 1336.4 (calc 1335.8) 
[M+6H]
6+
; 1145.3 (calc 1145.1) [M+7H]
7+
; MW 8008.7. 
12c: m/z 1659.1 (calc 1658.8) [M+5H]
5+
; 1383.5 (calc 1382.5) [M+6H]
6+
; 1185.6 (calc 1185.2) 
[M+7H]
7+
; MW 8289.1. 
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12d: m/z 1715.6 (calc 1714.9) [M+5H]
5+
; 1429.3 (calc 1429.3) [M+6H]
6+
; 1225.6 (calc 1225.2) 
[M+7H]
7+
; 1072.4 (calc 1072.2) [M+8H]
8+
; MW 8569.5. 
12e: m/z 2213.9 (calc 2213.5) [M+4H]
4+
; 1772.0 (calc 1771.0) [M+5H]
5+
; 1476.4 (calc 1476.0) 
[M+6H]
6+
; 1265.4 (calc 1265.3) [M+7H]
7+
; 1107.7 (calc 1107.2) [M+8H]
8+
; 984.9 (calc 984.3) 
[M+9H]
9+
 MW 8849.9. 
Synthesis of dendrimer- E6
43-57
/E7
44-57  
(6) 
 A mixture of 9 (8.5 mg, 3.6 µmol, 12 equiv.), 10 (2.4 mg, 1.2 µmol, 4 equiv.) and 8 (5.8 mg, 0.3 
µmol, 1 equiv.) was dissolved in DMF (1 mL), and a copper wire (60 mg) was added. The air in 
the reaction mixture was removed by nitrogen bubbling. The reaction mixture was covered and 
protected from light with aluminum foil and stirred at 50 °C under nitrogen for 10 h. The wires 
were filtered off from the warm solution and washed with 1 mL of DMF. Millipore endotoxin-
free water (7 mL) was slowly added to the solution (0.005 mL/min). Particles formed through the 
self-assembly process were exhaustively dialyzed against endotoxin-free water using presoaked 
and rinsed dialysis bags (Pierce Snakeskin, MWCO 3K). The final formulation was self-
assembled into particles with diameters above 143 μm as observed by laser diffraction method 
(Mastersizer 2000, Malvern Instruments, UK) after formulating the conjugate in PBS. 
Synthesis of 13
20
  
N-terminal acryloyl derivative of E6
43-57
 peptide epitope (13, CH
2
=CHCO-
QLLRREVYDFAFRDL) was synthesized following the general Fmoc-SPPS procedure. The 
attachment of acrylate (4.2 equiv.) was achieved using HATU (4 equiv.)/DIPEA (4.2 equiv.) at 
room temperature (2 × 1 h). The crude product was purified by preparative RP-HPLC on C-18 
column with solvent gradient 35-55% solvent B over 20 min. HPLC analysis (C-18 column): t
R
 = 
22.7 min, purity > 95%. Yield: 33%. ESI-MS: m/z 998.2 (calc 998.1) [M+2H]
2+
; 665.8 (calc 
665.8)  [M+3H]
3+
; MW 1994.3. 
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Synthesis of 14
20
  
N-terminus E7
44-57
 mercapto-azie peptide epitope (14, N
3
CH
2
CO-CQAEPDRAHYNIVTF-NH
2
) 
was synthesized following the general Fmoc-SPPS procedure. Fmoc deprotection of Thr, Val, 
and Ile were performed with 2% of 1,8-diazabicycloundec-7-ene (DBU) in DMF (twice, 5 and 10 
min) instead of 20% piperidine in DMF. The attachment of azidoacetic acid (4.2 equiv.) was 
achieved using HATU (3 equiv.)/DIPEA (4.2 equiv.) at room temperature (2 × 1 h) and the 
reaction mixture was covered and protected from light with aluminum foil. The crude product 
was purified by preparative RP-HPLC on C-18 column with solvent gradient 20-40% solvent B 
over 20 min. HPLC analysis (C-18 column): t
R
 = 18.3 min, purity > 95%. Yield: 72%. ESI-MS: 
m/z 924.0 (calc 924.0) [M+2H]
2+
; MW 1846. 
Synthesis of multiantigenic peptide azide (15) through mercapto-acrylate conjugation
20
  
A mixture of the two peptide epitopes acryloyl derivative of E6
43-57
 (13, 7.2 mg, 3 µmol, 1.0 
equiv.) and E7
44-57
 mercapto-azide (14, 13.4 mg, 6 µmol, 2 equiv.) was dissolved in a guanidine 
buffer at ~pH 7.3. The reaction mixture was incubated at 37 °C for 48 h. The progress of reaction 
was monitored by analytical HPLC until the acryloyl derivative 13 was completely consumed. 
The reaction mixture was purified by using semi-preparative HPLC C-18 column (20-60% 
solvent B over 60 min). After lyophilization the pure azide derivative 15 was obtained as an 
amorphous white powder. The product was detected using analytical HPLC analysis (C-4 
column), t
R
 = 21.8 min, purity > 97% and (C18 column), t
R
 = 21.4 min, purity > 95%.  
Yield: (12.2 mg, 90%). ESI-MS: m/z 1921.5 (calc 1921.1) [M+2H]
2+
; 1281.3 (calc 1281.1) 
[M+3H]
3+
; 961.2 (calc 961.1) [M+4H]
4+
; 768.9 (calc 769.1) [M+5H]
5+
; MW 3840.3.  
Synthesis of dendrimer- E6
43-57
-E7
44-57  
(7) 
 A mixture of azide derivative 15 (21.2 mg, 4.8 µmol, 16 equiv.) and 8 (5.8 mg, 0.3 µmol, 1 
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equiv.) was dissolved in DMF (1 mL), and a copper wire (60 mg) was added. The air in the 
reaction mixture was removed by nitrogen bubbling. The reaction mixture was covered and 
protected from light with aluminum foil and stirred at 50 °C under nitrogen for 15 h. The wires 
were filtered off from the warm solution and washed with 1 mL of DMF. Millipore endotoxin-
free water (7 mL) was slowly added to the solution (0.005 mL/min). Particles formed through the 
self-assembly process were exhaustively dialyzed against endotoxin-free water using presoaked 
and rinsed dialysis bags. The resulting particles were self-assembled into particles with diameters 
above 106 μm as observed by laser diffraction method after formulating the conjugate in PBS. 
Synthesis of Vaccine Candidates 1-4 
Synthesis of polymer-peptide conjugates 1-4
 
was performed as previously described
14
 and 
produced virtually identical products. Briefly, alkyne-functionalized poly(t-butyl acrylate) 
polymers with different number of alkyne moieties (1, 2, 4 and 8 alkyne moieties) 
 
were 
synthesized by atom-transfer radical polymerization (ATRP) and end-group functionalization.
14, 16
 
The E7
44-57
 azide (10) epitope was conjugated to different polymers via CuAAC “click” reaction 
to produce polymer-peptide conjugates 1-4. 
Particle size measurement  
The particle size and size distribution (span) of conjugate was measured by laser diffraction 
method (Mastersizer 2000, Malvern Instruments, UK) after formulating the conjugate in PBS. 
The geometrical diameter was presented as volume median diameter (D50%). The size 
distribution (span) value was defined by a standard formula: Span = (D90%-D10%)/D50%. 
Where D10%, D50% and D90% are the particle diameters determined at the 10
th
, 50
th
 and 90
th
 
percentile of the undersized particle distribution curve.
36
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Biological Assay 
Mice and Cell Lines. Female C57Bl/6 (6−8 weeks old) mice were used in this study and 
purchased from Animal Resources Centre (Perth, Western Australia). TC-1 cells (murine 
C57Bl/6 lung epithelial cells transformed with HPV-16 E6/E7 and ras oncogenes) were obtained 
from TC Wu.
37
 TC-1 cells were cultured and maintained at 37 °C/5% CO2 in RPMI 1640 
medium (Gibco) supplemented with 10% heat inactivated fetal bovine serum (Gibco) and 1% 
nonessential amino acid (Sigma-Aldrich). The animal experiments were approved by the 
University of Queensland Animal Ethics committee (DI/034/11/NHMRC) in accordance with 
National Health and Medical research Council (NHMRC) of Australia guidelines. 
In vivo tumor treatment experiments 
Experiment 1: Groups of C57Bl/6 mice (10 per group) were first challenged 
subcutaneously with 2  105 TC-1 tumor cells/mouse suspended in 100 μL 1 × PBS in the right 
flank (day 0), and rested for 7 days to allow for tumor formation. On the day 7 after tumor 
inoculation, the mice were received a single-dose subcutaneous immunization on each side of the 
tail base with 50 g (100 g in total) of polymer-peptide conjugates (1-4) in a total volume of 
100 L 1 × PBS or control formulations. Positive control received 30 g of E744-57 emulsified in 
a total volume of 100 L of Montanide ISA51 (Seppic, France)/PBS (1:1, v/v). Negative control 
was received 100 L 1 × PBS.  The size of the tumor was monitored every second days using 
calipers (and palpation) for 80 days.
38, 39 
The tumor volume was calculated using the formula:
39
 
Tumor volume (cm
3) = π × [largest diameter × (perpendicular diameter)2]/6. 
The mice were euthanized when tumor greater than 1 cm
3
 or started bleeding to avoid 
unnecessary suffering. 
Experiment 2: Compounds 4-7 were tested in the same manner as described above. The 
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size of the tumor was monitored every second days for 90 days. For the physical mixture (4 + 5), 
the mice were received a single-dose subcutaneous immunization on each side of the tail base 
with a mixture of 50 g of each compound in a total volume of 100 L 1 × PBS. The physical 
mixture (4 + 5) was prepared as follow: compounds 4 and 5 were self-assembled into particles 
separately via the solvent replacement method (DMF/water). Excess unreacted peptides, copper, 
and organic solvents were removed by extensive dialysis against water. Two equal amounts of 
both aliquots of 4 and 5 were mixed together.  
Positive control received 15 g of E744-57 and 15 g of E643-57 emulsified in a total 
volume of 100 L of Montanide ISA51 (Seppic, France)/PBS (1:1, v/v). Negative control was 
received 100 L of PBS. Compound 4 was also administered using “boost” regiment. Thus, mice 
in the group 4-boost received first dose on day 7 and additional boosts on day 14 and 21. All 
doses included 100 g of compound 4. 
Statistical Analysis 
All data were analyzed using GraphPad Prism 6 software. Kaplan-Meier survival curves 
for tumor treatment experiments were applied. Statistical analysis between groups was 
determined using the log-rank (Mantel-Cox) test for survival experiments. Differences were 
considered statistically significant for p  0.05.  
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